ArticleZeitschrift fur Rheumatologie2025
[Frequency of interstitial lung diseases in inpatient rheumatology : Retrospective analysis of inpatient diagnoses 2005-2023 in Germany].
Article in Zeitschrift fur Rheumatologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- [Survey of care situation for patients with systemic lupus erythematosus and systemic sclerosis with pulmonary involvement in Rhineland-Palatinate and Saarland].Zeitschrift fur Rheumatologie · 2026Article
- [Dealing with antibodies against dsDNA or nucleosomes under anti-TNF treatment].Zeitschrift fur Rheumatologie · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInterstitial lung disease (ILD) in inflammatory rheumatic diseases (IRD) is of great importance in the diagnostics and treatment. Due to the often complex and severe courses, inpatient care is often necessary. New data are needed regarding the frequency of lung involvement in general and the development of the proportion of inpatients in Germany.
methodsA retrospective analysis of the inpatient diagnoses published by the Federal Statistical Office according to the International Classification of Diseases (ICD-10) from 2005 to 2023 in Germany was carried out. A total of 11 main rheumatological diagnoses were analyzed, in particular rheumatoid arthritis (RA, M05, M06), connective tissue disease (M32-M35), ANCA-associated vasculitis (M30.1, M31.3, M31.7) and axial spondylarthritis (M45). The frequency of additionally coded secondary diagnoses of lung involvement (J84.1, J84.8, J84.9, J99.0*, J99.1*) was presented over a total observational period of 19 years.
resultsThere were between 50,540 and 64,004 inpatient stays per year with one of the main rheumatological diagnoses examined. The number rose to as high as 64,000 from 2005 to 2019, collapsed in 2020-2022 and stood at 54,077 in 2023. The proportion with coded lung involvement rose from 7% (3524 in 2005) to 17% (9398 in 2023). Lung involvement was most common in granulomatosis with polyangiitis (46%), systemic sclerosis (44%), Sjögren's syndrome (27%) and Sharp's syndrome (24%). In seropositive RA 8% and in seronegative RA 1% had lung involvement (data from 2023). DISCUSSION: During the period under study, the number of inpatient stays with a main rheumatological diagnosis in Germany increased, with a slump during the SARS-CoV 2 pandemic. The continuously increasing proportion of patients with lung involvement indicates the inpatient interdisciplinary care needs of this growing rheumatological patient group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.